Cao et al. (2020) reported that 6-(3-oxoindolin-2-ylidene)indolo(2,1-b)quinazolin-12-one, bicuculline, physciondiglucoside, dihydroverticillatine, and licoisoflavanone are compounds present in Shufeng Jiedu Capsule that could regulate the signaling pathways involved in human cytomegalovirus infection, Kaposi’s sarcoma-associated herpesvirus infection, the IL17 signaling pathway, and small cell lung cancer, which could be active to treat COVID-19 by binding with SARS-CoV-2 3CL hydrolase and ACE2. The gene discussed is IL17A; the disease is COVID-19.